Longitudinal algorithm may detect ovarian cancer earlier

December 21, 2012
Longitudinal algorithm may detect ovarian cancer earlier
Compared with a single-threshold rule, a parametric empirical Bayes longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

(HealthDay)—Compared with a single-threshold (ST) rule, a parametric empirical Bayes (PEB) longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

Charles W. Drescher, M.D., of the Fred Hutchinson Cancer Research Center in Seattle, and colleagues compared an ST rule with a PEB longitudinal screening algorithm in a retrospective evaluation of preclinical CA125 values measured annually in 44 participants with incident from the Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial.

The researchers found that, in many cases, ovarian cancer was detected earlier using the PEB algorithm, compared to using an ST rule. At a specificity of 99 percent, corresponding to an ST rule CA125 cut-off of ≥35 U/mL used in the PLCO trial, use of the PEB algorithm would have identified 20 percent of cases earlier. The PEB indicated abnormal CA125 values among these cases 10 months earlier and at a lower CA125 concentration (42 percent lower; 20 U/mL) than an ST rule cut-off. As the specificity of screening was reduced, there was an increase in the proportion of cases detected earlier by PEB.

"Our results demonstrated that, for ovarian by using , the PEB longitudinal algorithm detected ovarian cancer earlier than an ST rule in a statistically significant and meaningful proportion of cases," the authors write. "This observation was consistent across a range of specificities relevant for a first-line test in a multimodal ."

Explore further: Strict ovarian CA screening adherence called for in high-risk

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Strict ovarian CA screening adherence called for in high-risk

December 5, 2012
(HealthDay)—For women at higher risk for ovarian and/or fallopian tube cancer (OC/FTC), annual screening offers high sensitivity for detection of incident cancers, but few of these cancers are stage I or II, according to ...

FDA clears biomarker test for ovarian cancer

September 6, 2011
Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.